Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $32.07, for a total value of $240,525.00. Following the sale, the insider owned 32,316 shares of the company’s stock, valued at approximately $1,036,374.12. This trade represents a 18.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Tuesday, September 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.06, for a total value of $202,950.00.
• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $84,350.43.
• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.

Maze Therapeutics Trading Down 1.4%

NASDAQ:MAZE opened at $31.48 on Friday. The company’s 50 day moving average is $27.49 and its 200-day moving average is $31.99. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12 month low of $21.95 and a 12 month high of $53.65. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -12.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. BTIG Research reissued a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Citigroup initiated coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Wedbush reiterated an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday, September 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average target price of $64.45.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently made changes to their positions in the stock. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth $122,983,582. BlackRock Inc. acquired a new stake in shares of Maze Therapeutics during the second quarter worth $104,525,000. Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth $101,764,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics in the second quarter valued at about $41,435,000.

About Maze Therapeutics

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.